round logo Carthera RESEARCH & DEVELOPMENT
Proprietary platform

Carthera® is developing proprietary technologies as a platform to treat various severe brain diseases


Our goal is to offer easy, well integrated and cost-effective treatments to both patients and clinicians.

Carthera’s priority is to develop therapeutic approaches that will benefit patients with high unmet needs. With our partnered institutions, we are addressing neuro-oncological indications with adult and pediatric glioblastoma and brain metastases trials, as well as neuro-degenerative indications such as Alzheimer’s Disease.

logo-carthera RESEARCH AND DEVELOPMENT Our Pipeline

Place your mouse over each trial to discover more information
Program Indication Pre-clinical Phase 1 Phase 2 Phase 3 Marketed
Recurrent Glioblastoma
Recurrent Glioblastoma
Newly Diagnosed Glioblastoma
Brain metastases
Alzheimer’s Disease
Reccurent malignant pediatric brain tumors

Research & Development Non-clinical Pipeline

Extensive research ongoing with world-renowned laboratories.

Since 2010, a large series of pre-clinical studies have been conducted by Carthera® in collaboration with world-renowned research laboratories. Today, extensive translational research is being conducted in parallel with the SonoCloud® clinical development.

Non-clinical programs, mainly focused on combining the US-BBB opening by SonoCloud® with new cytotoxic agents and/or immunotherapy approaches (e.g. adoptive cellular therapy, immune checkpoint blockade), are presently ongoing with prestigious research centers.

There is a unique opportunity to ascertain if US-BBB opening, by providing an actionable target in the brain tumor, will work in synergy with ICIs

Dr. Amy Heimberger

Professor of Neurological Surgery, Northwestern University, Chicago